Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 6/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917031 | 0.89 | TP53 (0.51) | SMPD1PTPN11 | |
| SCHEMBL2917087 | 0.84 | CYP19A1 (0.46) | SMPD1PTPN11THRATHRBALDH1A1 | |
| SCHEMBL2948416 | 0.81 | LTC4S (0.48) | SMPD1PTPN11THRATHRB | |
| SCHEMBL24962415 | 0.80 | MAPT (0.49) | SMPD1PTPN11ALDH1A1HPGDS1PR3 | |
| SCHEMBL4518941 | 0.80 | SMPD1 (0.61) | SMPD1LTB4RTHRATHRBMGLL | |
| SCHEMBL2056260 | 0.79 | CREBBP (0.51) | SMPD1PTPN11ALDH1A1HPGD | |
| SCHEMBL4667829 | 0.79 | MAPT (0.45) | PTPN11ALDH1A1HPGD | |
| SCHEMBL3738882 | 0.78 | MAOA (0.49) | SMPD1PTPN11THRATHRBALDH1A1 | |
| SCHEMBL25788934 | 0.78 | MAOA (0.49) | SMPD1PTPN11THRATHRBALDH1A1 | |
| SCHEMBL30929659 | 0.78 | PTPN11 (0.69) | SMPD1PTPN11MGLLALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286215-A1 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | 2010-11-11 | — | — | US | disclosed |
| EP-2185504-A2 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009030887-A2 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286215-A1 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | LTC4S, LTB4R2, LTB4R | SMPD1 1397/4885PTPN11 4217/4885LTB4R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.